Direct inhibitory effects of Ganciclovir on ICAM-1 expression and proliferation in human coronary vascular cells

Rainer Voisard1, Ulrike Münder, Lutz von Müller

  • 1Department of Internal Medicine II-Cardiology, University of Ulm, Ulm, Germany. rainer@voisard.de

Abstract

Insights

Ganciclovir shows antiproliferative effects on coronary cells, partially due to cytotoxicity. Its impact on ICAM-1 expression and cell proliferation may be relevant in vivo for drug-eluting stents.

Area of Science:

  • Cardiovascular Research
  • Virology
  • Pharmacology

Background:

  • Human cytomegalovirus (HCMV) infection influences cardiovascular conditions like restenosis and atherosclerosis.
  • Ganciclovir treatment for HCMV infection has indirect benefits on these conditions.
  • This study investigates the direct effects of ganciclovir on key factors in coronary atherosclerosis.

Purpose of the Study:

  • To evaluate the direct impact of ganciclovir on intercellular adhesion molecule 1 (ICAM-1) expression.
  • To assess the direct impact of ganciclovir on endothelial and smooth muscle cell proliferation.
  • To determine the clinical relevance of ganciclovir's effects using SI/MPL-ratios.

Main Methods:

  • In vitro studies using cytoflow analysis on human umbilical vein endothelial cells (HUVEC), human coronary artery endothelial cells (HCAEC), and human coronary smooth muscle cells (HCMSMC).
  • Ganciclovir was administered at concentrations ranging from 0.05 to 5000 µg/mL.
  • Assessed TNF-α induced ICAM-1 expression, cell proliferation, and cytotoxic effects.

Main Results:

  • Ganciclovir exhibited slight but significant inhibition of ICAM-1 expression in all tested cell types.
  • Dose-dependent and significant antiproliferative effects of ganciclovir were observed across all cell types.
  • Cytotoxic effects partially contributed to the observed antiproliferative actions of ganciclovir.

Conclusions:

  • SI/MPL-ratios greater than 1 in HCAEC and HCMSMC suggest that ganciclovir's inhibitory effects on ICAM-1 and proliferation may occur in vivo.
  • These effects are likely relevant only with high local drug concentrations, such as those delivered by drug-eluting stents (DES).
  • Ganciclovir's direct cellular effects warrant consideration in the context of cardiovascular interventions.

Related Concept Videos

Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Immunoglobulin-like Cell Adhesion Molecules01:31

Immunoglobulin-like Cell Adhesion Molecules

Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...